p16 (INK4a, CDKN2A, cyclin-dependent kinase inhibitor 2A) is a tumor suppressor gene that is important in regulating cell cycle. Mutations in p16 can result in various cancers, most notably melanoma. p16 is a splice variant that comes from the gene CDKN2A. CDKN2A gene produces 2 major proteins, p16 (INK4) and p14 (ARF), which binds MDM2.
Product Information
Format
Culture Supernatant
Control
HEK293 whole cell lysate.
Presentation
Unpurified rabbit monoclonal IgG in buffer containing 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
Applications
Application
Please note that this product will not be available for sale after March 15, 2015. Please select one of the other antibodies against this target. Anti-p16/INK4a Antibody, clone EP435Y detects level of p16/INK4a & has been published & validated for use in WB, FC & IP.
Key Applications
Immunoprecipitation
Western Blotting
Flow Cytometry
Application Notes
Immunoprecipitation: A 1:50 dilution of a previous lot was used in IP.
Flow Cytometry: A 1:10 dilution of a previous lot was used in FC.
Biological Information
Immunogen
Recombinant p16/INK4a human protein
Clone
EP435Y
Host
Rabbit
Specificity
This antibody recognizes p16/INK4a.
Isotype
IgG
Species Reactivity
Human
Species Reactivity Note
Proven to react with human. Not expected to react with mouse and rat
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, MDM1, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq]
Function:Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. Ref.10 Subunit structure:Heterodimer with CDK4 or CDK6. Isoform 3 does not bind to CDK4. Tissue specificity:Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific. Ref.2 Polymorphism:Genetic variations in CDKN2A may underlie susceptibility to uveal melanoma [MIM:155720]. Uveal melanoma is the most common type of ocular malignant tumor, consisting of overgrowth of uveal melanocytes and often preceded by a uveal nevus. Involvement in disease:Defects in CDKN2A are involved in tumor formation in a wide range of tissues.
Defects in CDKN2A are the cause of cutaneous malignant melanoma 2 (CMM2) [MIM:155601]. Inheritance is autosomal dominant. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a preexisting benign nevus, which occurs most often in the skin but also may involve other sites.
Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719].
Defects in CDKN2A are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53.
Defects in CDKN2A are the cause of melanoma-astrocytoma syndrome [MIM:155755]. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Sequence similarities:Belongs to the CDKN2 cyclin-dependent kinase inhibitor family. Contains:4 ANK repeats.
Product Usage Statements
Quality Assurance
Routinely evaluated by Western Blot on HEK293 whole cell lysate.
Western Blot Analysis: A 1:500-1:2,000 dilution of this lot was used to detect p16/INK4a HEK293 whole cell lysate.
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions
Stable for 1 year at -20ºC from date of receipt.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. Note: Variability in freezer temperatures below -20°C may cause glycerol containing solutions to become frozen during storage.
p16 (INK4a, CDKN2A, cyclin-dependent kinase inhibitor 2A) is a tumor suppressor gene that is important in regulating cell cycle. Mutations in p16 can result in various cancers, most notably melanoma. p16 is a splice variant that comes from the gene CDKN2A. CDKN2A gene produces 2 major proteins, p16 (INK4) and p14 (ARF), which binds MDM2.
Product Information
Format
Culture Supernatant
Control
HEK293 whole cell lysate.
Presentation
Unpurified rabbit monoclonal IgG in buffer containing 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
Applications
Application
Please note that this product will not be available for sale after March 15, 2015. Please select one of the other antibodies against this target. Anti-p16/INK4a Antibody, clone EP435Y detects level of p16/INK4a & has been published & validated for use in WB, FC & IP.
Key Applications
Immunoprecipitation
Western Blotting
Flow Cytometry
Application Notes
Immunoprecipitation: A 1:50 dilution of a previous lot was used in IP.
Flow Cytometry: A 1:10 dilution of a previous lot was used in FC.
Biological Information
Immunogen
Recombinant p16/INK4a human protein
Clone
EP435Y
Host
Rabbit
Specificity
This antibody recognizes p16/INK4a.
Isotype
IgG
Species Reactivity
Human
Species Reactivity Note
Proven to react with human. Not expected to react with mouse and rat
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, MDM1, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq]
Function:Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. Ref.10 Subunit structure:Heterodimer with CDK4 or CDK6. Isoform 3 does not bind to CDK4. Tissue specificity:Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific. Ref.2 Polymorphism:Genetic variations in CDKN2A may underlie susceptibility to uveal melanoma [MIM:155720]. Uveal melanoma is the most common type of ocular malignant tumor, consisting of overgrowth of uveal melanocytes and often preceded by a uveal nevus. Involvement in disease:Defects in CDKN2A are involved in tumor formation in a wide range of tissues.
Defects in CDKN2A are the cause of cutaneous malignant melanoma 2 (CMM2) [MIM:155601]. Inheritance is autosomal dominant. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a preexisting benign nevus, which occurs most often in the skin but also may involve other sites.
Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719].
Defects in CDKN2A are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53.
Defects in CDKN2A are the cause of melanoma-astrocytoma syndrome [MIM:155755]. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Sequence similarities:Belongs to the CDKN2 cyclin-dependent kinase inhibitor family. Contains:4 ANK repeats.
Product Usage Statements
Quality Assurance
Routinely evaluated by Western Blot on HEK293 whole cell lysate.
Western Blot Analysis: A 1:500-1:2,000 dilution of this lot was used to detect p16/INK4a HEK293 whole cell lysate.
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions
Stable for 1 year at -20ºC from date of receipt.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. Note: Variability in freezer temperatures below -20°C may cause glycerol containing solutions to become frozen during storage.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
